AR9.6 / Quest PharmaTech, University of Nebraska, OncoCare Therap - LARVOL DELTA

Pretargeted alpha therapy in MUC16-positive high-grade serous ovarian cancer. (PubMed, Nucl Med Biol) - "We confirmed that pretargeting with AR9.6-TCO and [225Ac]Ac-mcp-PEG8-Tz has durable antitumor effects in high MUC16-expressing tumors. These findings demonstrate great potential for using pretargeting in combination with TAT for the treatment of ovarian cancer."

Journal • Hematological Disorders • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor • MUC16

Structural Basis of MUC16 Recognition by Antibody AR9.6 (FOB-USA 2024) - No abstract available

Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6. (PubMed, Mol Cancer Ther) - "The mechanism of action of huAR9.6 may depend on dense avid binding to homologous SEA domains on MUC16. The results of this study validate the translational therapeutic potential of huAR9.6 against MUC16-positive PDACs."

Journal • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • MUC16